Relapsed and Refractory Multiple Myeloma
Oncology·MeSH: Multiple Myeloma
Prevalence
17.0 / 100K
Incidence
7.0 / 100K/yr
2 drugs in development·1 company·2 clinical trials
Drug Pipeline by Phase
Phase 2(2)
Compare drugs
Frequently asked questions
How many drugs are in development for Relapsed and Refractory Multiple Myeloma?
BioSniper tracks 2 drugs in development for Relapsed and Refractory Multiple Myeloma across 1 company.
How many clinical trials target Relapsed and Refractory Multiple Myeloma?
There are 2 clinical trials targeting Relapsed and Refractory Multiple Myeloma tracked by BioSniper.
What is the prevalence of Relapsed and Refractory Multiple Myeloma?
The estimated prevalence of Relapsed and Refractory Multiple Myeloma is approximately 17.0 per 100,000 population.
Deep-dive into Relapsed and Refractory Multiple Myeloma
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis